- Presentation expands on survival data which showed a 12-month disease-free survival (DFS) of 81.1%
- Patients with post-treatment TIL levels had 95.0% 12-month DFS compared with 64.9% in patients with lower TIL levels
- Patients with treatment-related hyalinisation and fibrosis greater than 52% had 93.8% 12-month DFS
- Results build on previously reported strong pathological responses and further support the potential of efti-based combination therapy
Immutep (ASX: IMM) has unveiled new data from an investigator-initiated EFTISARC-NEO Phase II study evaluating radiotherapy before surgery in patients with high-risk, resectable soft tissue sarcoma.
The study focused on Immutep’s eftilagimod alfa (efti) in combination with KEYTRUDA (pembrolizumab).
Forty patients were enrolled and 38 patients underwent surgery and were included in the survival evaluation.
The latest analysis currently shows a disease-free survival (DFS) of 81.1% at 12 months. The current Kaplan-Meier estimate at 18 months is also 81.1%, although this later time point remains immature, and follow-up is ongoing.
Among the 38 patients who underwent surgery and were evaluated, eight patients had experienced disease recurrence at the data cut-off.
In addition, exploratory analyses showed that higher levels of tumour-infiltrating lymphocytes (TILs) and greater hyalinisation and fibrosis after treatment may be associated with better DFS.
In particular, patients with post-treatment TIL levels above 310 cells/mm2 had 95.0% 12-month DFS compared with 64.9% in patients with lower TIL levels.
Patients with treatment-related hyalinisation and fibrosis greater than 52% had 93.8% 12-month DFS compared with 71.4% in patients with lower levels of hyalinisation and fibrosis. The presence of tertiary lymphoid structures (TLS) and baseline expression of PD-L1, LAG-3 and TIGIT did not correlate with survival outcomes.
“With the data to date, EFTISARC-NEO is delivering an increasingly coherent and encouraging picture,” CEO, Marc Voigt, said.
“The marked difference in outcomes between patients with higher and lower post-treatment immune cell infiltration is especially notable and is consistent with efti’s potential to help generate a stronger anti-tumour immune response.
“We believe these results strengthen the rationale for further potential clinical development in this indication, where patients remain in need of more effective treatment options.”
Immutep anticipates reporting additional data from EFTISARC-NEO in CY2027.
Subject to regulatory interactions, manufacturing timelines, partnering arrangements and available resources, the company is preparing to advance efti into a registration-directed clinical trial in neoadjuvant soft tissue sarcoma, targeting initiation in H2 CY2027.
IMM was steady at 2.3¢ with a Mkt cap of $33.89M.
Join the discussion: See what HotCopper users are saying about Immutep and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
